FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2980250637> ?p ?o ?g. }

• W2980250637 abstract "Abstract Abstract 682 Background: Follicular lymphoma (FL) is the most common indolent lymphoma and is clinically characterized by slow progression and responsiveness to therapy, but almost inevitable disease recurrences. While patient outcomes are generally favorable, a substantial proportion of patients are at risk of early death due to treatment resistance, early progression or transformation. CD68 positive macrophages were shown to predict poor survival in the pre-rituximab era (Farinha et al., Blood 2005 Sep 15;106(6):2169–74), but their association with poor outcome was lost or even reversed since the introduction of rituximab into the routine management of FL (Taskinen et al, Clin Cancer Res. 2007 Oct 1;13(19):5784–9 and Canioni et al, J Clin Oncol. 2008 Jan 20;26(3):440–6). Macrophages can be broadly divided into M1 and M2 subtypes with the latter associated with pro-tumoral immunity. We hypothesize that CD68 alone insufficiently captures the various phenotypes of tumor-associated macrophages and that staining for CD163 as a marker for alternatively activated macrophages (M2) provides additional prognostic information. Methods: We constructed a tissue microarray (TMA) from formalin-fixed and paraffin-embedded tissue blocks of 187 systemic treatment-naive FL patients that were selected from the Lymphoid Cancer Database of the BC Cancer Agency and that had been uniformly treated between 2004 and 2010 with rituximab, cyclophosphamide, vincristine and prednisone (R-CVP). Since 2006, institutional guidelines recommended maintenance with rituximab for patients achieving a complete or partial remission after first-line therapy. Median follow-up of living patients was 56 months. Immunohistochemistry was performed on the TMA with antibodies against CD68 (clone KP1, DAKO) and CD163 (clone 10D6, Novocastra) and was analyzed by computer image analysis (Aperio) using the Positive Pixel Count algorithm. Disease-specific survival (DSS) served as the primary end-point, and progression-free survival (PFS) and time to transformation (TTT) as secondary endpoints. The statistical software X-tile was used to determine the optimum thresholds for CD68 and CD163 as the values that maximized the Chi-square value of the log-rank test. Results: Within the cores on the TMA, the mean percentage of positivity was 4.7% for CD68 (range 0.3–22.6%) and 1.8% for CD163 (range 0–13.7%). Above a threshold of 1.8%, high CD68 expression was associated with favorable DSS (p=0.03), but not with PFS (p=0.47) or TTT (p=0.82). Increased CD163 expression on the other hand, above a threshold of 1.1%, was significantly associated with poor DSS (p<0.01), but not with PFS (p=0.68) or time to transformation (p=0.13). When adjusting for the International Prognostic Index (IPI) in a Cox regression model, the association of high CD68 expression with favorable DSS (hazard ratio=0.42, p=0.05) and high CD163 expression with poor DSS (hazard ratio=2.93, p=0.01) remained significant. The correlation between CD68 and CD163 expression was low (Pearson correlation coefficient=0.25), suggesting that both markers define different subsets of tumor-associated macrophages. To explore whether additional prognostic information could be gained from combining these markers, we grouped CD68-high and CD163-low cases into one category (n=83) and compared them against all others (n=102). High CD68 and low CD163 expression was associated with favorable DSS (p<0.01), but not PFS (p=0.40) or TTT (p=0.21). Patients with high CD68 and low CD163 expression had excellent outcomes at 7 years of follow-up (96% DSS versus 68%). The impact on DSS remained significant after adjusting for IPI in a Cox regression model (hazard ratio=0.15, p<0.01). Conclusion: In FL patients treated with uniform induction therapy, CD163 defines a subset of tumor-associated macrophages that is associated with inferior DSS, but not with early progression or transformation, whereas the combination of CD68-high and CD163-low defines a patient category that has excellent prognosis. Our results suggest that the detrimental role of alternatively activated M2 type macrophages is not reversed by rituximab and that a population of non-tumor promoting macrophages exists that is correlated with favorable outcome in FL. Our study also illustrates the power of image analysis to provide accurate scoring, capable of delineating patient populations at variable risk of death. Disclosures: Al-Tourah: F. Hoffmann-La Roche (Roche Canada): Research Funding. Moccia:F. Hoffmann-La Roche (Roche Canada): Research Funding. Connors:F. Hoffmann-La Roche (Roche Canada): Research Funding. Sehn:F. Hoffmann-La Roche (Roche Canada): Research Funding." @default.
• W2980250637 created "2019-10-18" @default.
• W2980250637 creator A5012208236 @default.
• W2980250637 creator A5021115725 @default.
• W2980250637 creator A5021133318 @default.
• W2980250637 creator A5022658681 @default.
• W2980250637 creator A5026641386 @default.
• W2980250637 creator A5031758990 @default.
• W2980250637 creator A5048030695 @default.
• W2980250637 creator A5059082232 @default.
• W2980250637 creator A5070959932 @default.
• W2980250637 creator A5075117420 @default.
• W2980250637 date "2012-11-16" @default.
• W2980250637 modified "2023-09-27" @default.
• W2980250637 title "Tumor-Associated Macrophages Predict Outcome in Follicular Lymphoma" @default.
• W2980250637 doi "https://doi.org/10.1182/blood.v120.21.682.682" @default.
• W2980250637 hasPublicationYear "2012" @default.
• W2980250637 type Work @default.
• W2980250637 sameAs 2980250637 @default.
• W2980250637 citedByCount "0" @default.
• W2980250637 crossrefType "journal-article" @default.
• W2980250637 hasAuthorship W2980250637A5012208236 @default.
• W2980250637 hasAuthorship W2980250637A5021115725 @default.
• W2980250637 hasAuthorship W2980250637A5021133318 @default.
• W2980250637 hasAuthorship W2980250637A5022658681 @default.
• W2980250637 hasAuthorship W2980250637A5026641386 @default.
• W2980250637 hasAuthorship W2980250637A5031758990 @default.
• W2980250637 hasAuthorship W2980250637A5048030695 @default.
• W2980250637 hasAuthorship W2980250637A5059082232 @default.
• W2980250637 hasAuthorship W2980250637A5070959932 @default.
• W2980250637 hasAuthorship W2980250637A5075117420 @default.
• W2980250637 hasConcept C104317684 @default.
• W2980250637 hasConcept C121608353 @default.
• W2980250637 hasConcept C126322002 @default.
• W2980250637 hasConcept C127716648 @default.
• W2980250637 hasConcept C142724271 @default.
• W2980250637 hasConcept C143998085 @default.
• W2980250637 hasConcept C203014093 @default.
• W2980250637 hasConcept C204232928 @default.
• W2980250637 hasConcept C2775858924 @default.
• W2980250637 hasConcept C2776460901 @default.
• W2980250637 hasConcept C2776694085 @default.
• W2980250637 hasConcept C2776755627 @default.
• W2980250637 hasConcept C2777058707 @default.
• W2980250637 hasConcept C2779338263 @default.
• W2980250637 hasConcept C2779429289 @default.
• W2980250637 hasConcept C2780653079 @default.
• W2980250637 hasConcept C55493867 @default.
• W2980250637 hasConcept C71924100 @default.
• W2980250637 hasConcept C86803240 @default.
• W2980250637 hasConceptScore W2980250637C104317684 @default.
• W2980250637 hasConceptScore W2980250637C121608353 @default.
• W2980250637 hasConceptScore W2980250637C126322002 @default.
• W2980250637 hasConceptScore W2980250637C127716648 @default.
• W2980250637 hasConceptScore W2980250637C142724271 @default.
• W2980250637 hasConceptScore W2980250637C143998085 @default.
• W2980250637 hasConceptScore W2980250637C203014093 @default.
• W2980250637 hasConceptScore W2980250637C204232928 @default.
• W2980250637 hasConceptScore W2980250637C2775858924 @default.
• W2980250637 hasConceptScore W2980250637C2776460901 @default.
• W2980250637 hasConceptScore W2980250637C2776694085 @default.
• W2980250637 hasConceptScore W2980250637C2776755627 @default.
• W2980250637 hasConceptScore W2980250637C2777058707 @default.
• W2980250637 hasConceptScore W2980250637C2779338263 @default.
• W2980250637 hasConceptScore W2980250637C2779429289 @default.
• W2980250637 hasConceptScore W2980250637C2780653079 @default.
• W2980250637 hasConceptScore W2980250637C55493867 @default.
• W2980250637 hasConceptScore W2980250637C71924100 @default.
• W2980250637 hasConceptScore W2980250637C86803240 @default.
• W2980250637 hasLocation W29802506371 @default.
• W2980250637 hasOpenAccess W2980250637 @default.
• W2980250637 hasPrimaryLocation W29802506371 @default.
• W2980250637 hasRelatedWork W1763242238 @default.
• W2980250637 hasRelatedWork W2092717964 @default.
• W2980250637 hasRelatedWork W2140701272 @default.
• W2980250637 hasRelatedWork W2421552586 @default.
• W2980250637 hasRelatedWork W2473984749 @default.
• W2980250637 hasRelatedWork W2531118285 @default.
• W2980250637 hasRelatedWork W2531436564 @default.
• W2980250637 hasRelatedWork W2551458203 @default.
• W2980250637 hasRelatedWork W2551971707 @default.
• W2980250637 hasRelatedWork W2552034981 @default.
• W2980250637 hasRelatedWork W2570893191 @default.
• W2980250637 hasRelatedWork W2575167139 @default.
• W2980250637 hasRelatedWork W2586240524 @default.
• W2980250637 hasRelatedWork W2600694132 @default.
• W2980250637 hasRelatedWork W2942989498 @default.
• W2980250637 hasRelatedWork W2979720377 @default.
• W2980250637 hasRelatedWork W3162266419 @default.
• W2980250637 hasRelatedWork W3212158252 @default.
• W2980250637 hasRelatedWork W63538626 @default.
• W2980250637 hasRelatedWork W2977897352 @default.
• W2980250637 isParatext "false" @default.
• W2980250637 isRetracted "false" @default.
• W2980250637 magId "2980250637" @default.
• W2980250637 workType "article" @default.